ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review

By sjmartinez • June 18, 2024

Kathuria-Prakash N, Lopez LP, Raman S, Ye H, Anaokar J, Sisk A, Pantuck AJ, Drakaki A. ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review. JCO Precis Oncol. 2024 Jun;8:e2400154. doi: 10.1200/PO.24.00154. PMID: 38885453.

Tags: Fellow, Hematology/Oncology, Publications

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial

Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, Kang M, Wu SY, Lauche O, Ahn MJ, Yang MH, Lien MY, Metcalf[...]

Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report

Huynh J, Eisenbud L, Gutierrez R, Chuang FL, Dichter D. Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report. Cureus. 2026[...]

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

Doroshow DB, Leal TA, Waqar SN, Borghaei H, Camidge DR, Dragnev KH, Edelman MJ, Gandara DR, Gerber DE, Gray JE, Hirsch FR, Husain H, Kozono[...]